APSA-02 is under clinical development by Armata Pharmaceuticals and currently in Phase II for Bacteremia. According to GlobalData, Phase II drugs for Bacteremia have a 66% phase transition success ...

APPA-02 is under development for the treatment of multidrug-resistant chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients and non-CF bronchiectasis (NCFB). The drug ...

Merck & Co.’s Covid-19 antivirals are getting a new lease of life in post-pandemic China, as cat owners seize on them as ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Shares of Merck & Co. Inc. MRK slipped 0.03% to $99.14 Friday, on what proved to be an all-around great trading session for ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...

Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...

Shares of Merck & Co. Inc. MRK slumped 0.31% to $99.17 Thursday, on what proved to be an all-around dismal trading session ...